Document is current
Any future updates will be listed below
-
Authors
Grothusen, Grant P. https://orcid.org/0000-0001-9236-0369
Chang, Renxu
Cao, Zhendong
Zhou, Nan
Mittal, Monika
Datta, Arindam
Wulfridge, Phillip
Beer, Thomas
Wang, Baiyun https://orcid.org/0000-0003-2489-817X
Zheng, Ning https://orcid.org/0000-0002-1039-1581
Tang, Hsin-Yao https://orcid.org/0000-0003-1838-018X
Sarma, Kavitha https://orcid.org/0000-0002-3045-210X
Greenberg, Roger A. https://orcid.org/0000-0003-1326-8981
Shi, Junwei https://orcid.org/0000-0002-8427-6316
Busino, Luca https://orcid.org/0000-0001-6758-9276
-
Funding
Funding for this research was provided by:
Center for Strategic Scientific Initiatives, National Cancer Institute (R01-CA258904)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL159175)
American Cancer Society (RSG-19-199-01)
- License Information
-
More Information
Article History
Received: 3 August 2023
Accepted: 21 June 2024
First Online: 3 July 2024
Competing interests
: R.A.G. is a co-founder of RADD Pharmaceuticals and an advisor to Dong-A ST and TrevarX Biomedical, Inc. N.Zheng is a co-founder of and has financial interests in Seed Therapeutics and Molecular Glue Labs Ltd. N. Zheng also serves as a member of the scientific advisory board of SyntheX with financial interests. The remaining authors declare no competing interests.
